FDA Lets Capricor Resubmit Deramiocel Data Post Panel Vote — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capricor's deramiocel received a negative FDA advisory committee vote last week on its secondary endpoint, which measured heart function stabilization in a broader Duchenne population that included boys whose hearts were still stable.
- Data on heart stabilization was "much noisier" in the broader population than in the subpopulation that already had signs of heart dysfunction, the source notes.
- The FDA chose to allow Capricor to submit additional upper-limb data and analyses to refocus on the primary outcome, weighing the time a new biologic licensing application would take against patient lives and function lost during that delay.
- The drug's primary endpoint is the Performance of Upper Limb (PUL) test, which divides measurements into shoulder, arm, and hand domains — the article argues that choosing a total score versus a single domain creates a trade-off between capturing meaningful change in weaker or stronger participants and introducing statistical noise.
- Opinion author Mindy Leffler, who developed the Duchenne Video Assessment used in Capricor's Phase 3 study and consults on its data, said her son has taken deramiocel for five years and is preparing to start his second year of a master's degree program.
- Rare-disease trial design involves "hundreds of tiny decisions" on inclusion criteria and endpoint composition made with no certainty about each choice's downstream impact, the article argues, because sponsors are "blazing the trail."
Why it matters: For Duchenne families whose sons are stable on deramiocel, the FDA's willingness to accept additional upper-limb data rather than require a brand-new study preserves treatment continuity and years of preserved function. The decision also sets a precedent for how regulators balance pre-specification against the need to "learn as you go" in rare-disease trials where every protocol choice shapes a tiny patient pool.
Ask SkimNews
